To assess the potential protective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the onset of dementia, including vascular dementia (VaD), Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), in patients with type 2 diabetes mellitus (T2DM) compared to those treated with dipeptidyl peptidase-4 inhibitors (DPP4i).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: